Endoglin Mediates Vascular Maturation by Promoting Vascular Smooth Muscle Cell Migration and Spreading

Hongyu Tian, Tatiana Ketova, Duriel Hardy, Xiaojiang Xu, Xia Gao, Andries Zijlstra, Gerard C. Blobe

Objective—Endoglin, a transforming growth factor-β superfamily coreceptor, is predominantly expressed in endothelial cells and has essential roles in vascular development. However, whether endoglin is also expressed in vascular smooth muscle cells (VSMCs), especially in vivo, remains controversial. Furthermore, the roles of endoglin in VSMC biology remain largely unknown. Our objective was to examine the expression and determine the function of endoglin in VSMCs during angiogenesis.

Approach and Results—Here, we determine that endoglin is robustly expressed in VSMCs. Using CRISPR/CAS9 knockout and short hairpin RNA knockdown in the VSMC/endothelial coculture model system, we determine that endoglin in VSMCs, but not in endothelial cells, promotes VSMCs recruitment by the endothelial cells both in vitro and in vivo. Using an unbiased bioinformatics analysis of RNA sequencing data and further study, we determine that, mechanistically, endoglin mediates VSMC recruitment by promoting VSMC migration and spreading on endothelial cells via increasing integrin/FAK pathway signaling, whereas endoglin has minimal effects on VSMC adhesion to endothelial cells. In addition, we further determine that loss of endoglin in VSMCs inhibits VSMC recruitment in vivo.

Conclusions—These studies demonstrate that endoglin has an important role in VSMC recruitment and blood vessel maturation during angiogenesis and also provide novel insights into how discordant endoglin function in endothelial and VSMCs may regulate vascular maturation and angiogenesis.

Visual Overview—An online visual overview is available for this article. (Arterioscler Thromb Vasc Biol. 2017;37:1115-1126. DOI: 10.1161/ATVBAHA.116.308859.)

Key Words: endoglin • endothelial cells • integrins • muscle, smooth, vascular • signal transduction

Angiogenesis is the process through which new blood vessels form from pre-existing blood vessels. The process of angiogenesis begins with vasodilation, increased vascular permeability, and extracellular matrix (ECM) degradation in response to an angiogenic stimulus such as VEGF (vascular endothelial growth factor). Activated endothelial cells (ECs) proliferate and migrate toward the angiogenic stimulus, assemble into solid cords, and subsequently acquire a lumen. Once the new vessel has been assembled, pericytes and vascular smooth muscle cells (VSMCs) are recruited and migrate to the newly formed vessel to stabilize the nascent vessel in a quiescent state. Hence, proper cell–cell communication between ECs, pericytes, and VSMCs is critical for vascular remodeling and maturation.

Endoglin is a 95-kDa glycoprotein that directly binds TGF-β1 (transforming growth factor-beta 1) and BMP-9 (bone morphogenetic protein-9) and can bind TGF-β3, Activin A and BMP-2/7 in conjunction with their respective ligand binding receptors. Endoglin has been reported to either increase or decrease TGF-β superfamily signaling in ECs in vitro. In addition, endoglin also regulates non-Smad or non-TGF-β pathways to regulate endothelial biology via interaction with other proteins, including β-arrestin, zyxin or zyxin-related protein-1, and α5β1 integrin.

Endoglin has an important role in angiogenesis, as mice lacking endoglin die at embryonic days 10.5 to 11.5 because of defects in angiogenesis. Mutation of Endg results in type 1 hereditary hemorrhagic telangiectasia 1, a vascular disease, characterized by dilated vessels and arteriovenous malformations that lead to recurrent hemorrhage and shunting in the lung, brain, and the gastrointestinal tract. In addition, endoglin is overexpressed in neoangiogenic vessels, during inflammation, and in solid tumors. Although previous studies have focused largely on the roles of endoglin as a TGF-β superfamily coreceptor in ECs, these findings cannot fully explain the roles of endoglin in developmental and pathological angiogenesis. For example, a defect of VSMCs recruitment was found in endoglin knockout embryos.
However, in a neonatal retinal vascular development model, endoglin-specific knockout in ECs did not decrease VSMC recruitment by arteries, but increased VSMC recruitment by veins. In patients with hereditary hemorrhagic telangiectasia, in addition to EC defects, mural cell defects, including increased layers of smooth muscle cells and an in increase in stress fibers in pericytes, have been reported. Furthermore, endoglin deletion mediated by SM22α-Cre (smooth muscle protein 22 α-Cre), which results in recombination in ≈100% of arterial SMCs, including in the aorta but is exceptionally rare in ECs, caused arteriovenous malformations in the postnatal brain, spinal cord, and intestines. However, conditionally overexpressing endoglin in VSMCs in endoglin null embryos partially rescues VSMCs recruitment. In addition, endoglin is expressed in other non-ECs, including neural crest stem cells and smooth muscle cells in human atherosclerotic plaques or after arterial injury. Previous reports also demonstrated that endoglin is expressed in normal primary VSMCs in vitro, in freshly isolated VSMCs from human aorta, and in rare VSMCs in vivo, whereas another report detected no endoglin in normal VSMCs in vivo. Taken together, these studies suggest that endoglin in the vascular support cells, including VSMCs, may be important for angiogenesis and the pathogenesis of endoglin-associated diseases, including hereditary hemorrhagic telangiectasia. Here, we investigate the expression and roles of endoglin in VSMCs.

Materials and Methods

Materials and Methods are available in the online-only Data Supplement.

Results

Endoglin Promotes VSMC Recruitment During Angiogenesis In Vitro

To investigate endoglin’s roles in non-ECs during angiogenesis, we investigated whether endoglin is expressed in VSMCs. Consistent with a recent report, we determined that endoglin is robustly expressed in a panel of human primary VSMCs, including umbilical artery smooth muscle cells, pulmonary artery smooth muscle cells (PASMC), and aortic smooth muscle cells at both the mRNA (Figure IA in the online-only Data Supplement) and cell surface protein levels (Figure IB in the online-only Data Supplement). To obtain more direct evidence that endoglin is also expressed in VSMCs in vivo, we stained murine lung tissue using endoglin antibody, endothelial marker, CD31, and smooth muscle cells’ marker, α-smooth muscle actin. Both endothelial and VSMCs expressed endoglin (Figure 1A; Figure IC in the online-only Data Supplement). However, smooth muscle cells in the airway expressed low levels of endoglin (Figure 1A; right panel of Figure IC in the online-only Data Supplement). Furthermore, as aorta has multiple layers of VSMCs, we stained endoglin in mouse aorta using immunohistochemistry with peroxidase and counterstain. Endoglin is expressed in the multilayered media of both abdominal and ascending aorta (Figure 1B; Figure ID in the online-only Data Supplement). In addition, consistent with previous report, we also detected endoglin expression at mRNA level (Figure 1C) and cell surface protein level (Figure 1D) in the primary VSMCs and ECs (ECs) isolated from the murine aorta. These data indicate that VSMCs also express endoglin.

To investigate endoglin’s role in VSMC recruitment, we performed endothelial/VSMC cells coculture experiments in transwells (Figure 1E). CRISPR-induced endoglin knockout (ENG−/−; Figure IE in the online-only Data Supplement) or short hairpin RNA (shRNA)-mediated silencing of endoglin expression (shENG; Figure IE and IF in the online-only Data Supplement) in PASMC cells dramatically decreased PASMC recruitment by ECs (Figure 1F and 1G). However, murine EC lines generated from endoglin knockout mice (MEC−/−) either had no effect or slightly increased PASMCs recruitment compared with wild-type MEEC cells (MEC+/+; Figure 1F and 1G). These effects were specifically because of loss of endoglin, as restoring endoglin expression in ENG−/− PASMC cells (Figure 1G in the online-only Data Supplement) rescued recruitment (Figure 1H in the online-only Data Supplement). In addition, shRNA-mediated silencing of endoglin in PASMC cells also inhibited PASMC cells being recruited by (Figure 1H and 1I) and spreading on (Figure 1J) HMEC-1 (human microvascular endothelial cell-1) endothelial tubules formed on Matrigel. These data support a specific role for endoglin in VSMCs in promoting VSMC recruitment and spreading on ECs during angiogenesis.

Endoglin Promotes VSMC Recruitment via Increasing Migration

A recent study demonstrated that endoglin promotes VSMC adhesion to the ECs during vascular development. As there are multiple steps involved in VSMC recruitment, including migration, adhesion, and spreading, to obtain unbiased insight into how endoglin may regulates VSMC biology, we performed RNA sequencing (RNA-SEQ; GSE78271) with control and CRISPR-induced endoglin knockout PASMC cells. Among 26440 genes detected, there were 1623 differential expressed genes (Figure 2A; Data set I in the online-only Data Supplement). We analyzed the potential molecular and cellular functions implicated by the 1623 differential expressed genes using Ingenuity pathway analysis software. Based on this unbiased analysis, the molecular and cellular functions most affected by loss of endoglin expression in VSMCs was
Figure 1. Endoglin promotes vascular smooth muscle cells (VSMC) recruitment. A, Fluorescent staining of endoglin (red), α-smooth muscle actin (SMA; green), CD31 (white), and DAPI (4',6-diamidino-2-phenylindole; blue) in murine lung tissue. B, Immunohistochemistry staining of endoglin in murine abdominal aorta and ascending aorta, goat IgG was used as a negative control for antienoglin staining. C and D, mRNA (C) and cell surface protein (D) levels in primary VSMCs and endothelial cells (ECs) isolated from murine aorta detected using quantitative real-time polymerase chain reaction assay (C) and cell surface protein biotinylation assay (D). E, Schematics for VSMC/endothelial recruitment coculture transwell model. F and G, Confluent mouse embryonic endothelial cell (MEEC)+/− or MEEC−/− cells were cultured in the bottom transwell in blank medium for 24 h. Nontargeted control (NTC) pulmonary artery smooth muscle cell (PASMC) cells, ENG−/− (F), or shENG (G) PASMC cells were plated in the upper chamber and allowed to migrate for 24 h toward ECs. Recruited PASMC were quantified from 3 independent experiments with triplicates ±SEM. H–J, HMEC-1 cells were stained with red fluorescence and plated on Matrigel for 12 h to form tubules. shNTC or shENG PASMC cells (green) were plated and cultured for 6 h. The percentage of recruited PASMC cells (I) and normalized PASMC spreading on the endothelial tubules (J) were quantified from 3 independent experiments ± SEM.
cellular movement (Figure 2B), including VSMC movement and cell recruitment (Figure 2C).

As cell movement plays a pivotal role in VSMC recruitment during angiogenesis, we investigated whether endoglin promotes VSMC recruitment via promoting VSMC migration. shRNA-mediated silencing of endoglin expression (Figure 2D and 2E) or CRISPR-induced endoglin knockout (Figure 2F) potently inhibited PASMC migration as assessed using wound healing (Figure 2D) or transwell migration assay (Figure 2E and 2F). In addition, CRISPR-induced endoglin knockout also inhibited PASMC migration in transwells coated with collagen (Figure IIA in the online-only Data Supplement). In a reciprocal manner, overexpression of endoglin (Figure IIB in the online-only Data Supplement) increased PASMC migration (Figure 2G).

The ability of endoglin to promote VSMC cell migration was specific, as consistent with our previous reports,11,14,33 loss of endoglin in MEEC cells (MEEC−/−) increased EC migration in noncoated tranwells (Figure IIC in the online-only Data Supplement) or collagen-coated tranwells (Figure IID in the online-only Data Supplement). MEEC−/− cells also migrated more than MEEC+/+ cells in a wound healing model (Figure IIE in the online-only Data Supplement). Endoglin’s effect on VSMC migration occurred in a TGF-β superfamily signaling-independent manner, as the TGF-β superfamily ligands for endoglin, TGF-β1, and BMP-9 (Figure 2H),
and activin receptor-like kinase (ALK) 1 and ALK5 inhibitors (ALK1-FC and SB-431542, Figure 2I) did not significantly regulate VSMC migration in the presence or absence of endoglin. These studies support a cell-type-dependent effect of endoglin in regulating cell migration, with endoglin in VSMC promoting VSMC migration, and endoglin in ECs inhibiting endothelial migration.

**Endoglin Promotes VSMC Spreading**

We then turned our attention to endoglin-mediated VSMC adhesion and spreading, which are important in the later stages of VSMC recruitment and blood vessel maturation. shRNA-mediated silencing of endoglin in PASMCs slightly promoted PASMC cell adhesion to HMEC-1 ECs (Figure 3A and 3B) and decreased PASMC cell spreading on HMEC-1 cells (Figure 3A and 3C). Fibronectin, collagen, and laminin have prominent roles in regulating angiogenesis. To determine which ECM components are involved in endoglin-regulated VSMC adhesion and spreading, we assessed adhesion and spreading on the ECM components in both ECs and VSMCs. Loss of endoglin expression increased MEEC endothelial adhesion to all of these ECM components (Figure IIIA in the online-only Data Supplement). However, shRNA-directed knockdown of endoglin had modest effects on increasing PASMC adhesion to these ECM components (Figure IIIB in the online-only Data Supplement), whereas CRISPR-directed knockout endoglin had no effect (Figure IIIC in the online-only Data Supplement). This is consistent with Kyoto Encyclopedia of Genes and Genomes analysis of the RNA-SEQ data, in which cell adhesion pathways were not significantly affected ($P=0.06$) by CRISPR-induced endoglin knockout (Table I and Figure IIID in the online-only Data Supplement). However, CRISPR-induced endoglin knockout (Figure 3D and 3E) or shRNA-mediated silencing of endoglin expression (Figure 3F) in PASMCs significantly decreased PASMC spreading on these 3 different ECM components, whereas MEEC−/− endothelial spreading was modestly decreased on fibronectin, not affected on laminin and slightly increased on collagen (Figure IIIE and IIIF in the online-only Data Supplement). These data suggest that endoglin in VSMCs promotes blood vessel maturation by promoting VSMC spreading on ECs via different ECM components.

**Endoglin Promotes VSMC Recruitment and Spreading Via the Focal Adhesion Kinase Signaling**

To further investigate the mechanism by which endoglin promotes VSMC recruitment and spreading, we analyzed the differentially expressed genes regulated by endoglin in VSMCs using the Kyoto Encyclopedia of Genes and Genomes database and DAVID software (https://david.ncifcrf.gov). Many of these endoglin-regulated genes belonged to the ECM-receptor interaction and focal adhesion categories (Figure 4A; Table I in the online-only Data Supplement), both of which have a central role in cell migration and spreading. Accordingly, we investigated whether endoglin regulates VSMC recruitment and spreading via the ECM-integrin-focal

---

**Figure 3.** Endoglin promotes vascular smooth muscle cell (VSMC) spreading. **A–C,** sh-nontargeted control (NTC) or shENG pulmonary artery smooth muscle cell (PASMC) cells (green) were plated on confluent HMEC-1 cells (red) and cultured for 1 h. Cell adhesion (B) and spreading (C) were normalized and quantified from 3 independent experiments ± SEM. **D–F,** NTC (or shNTC), ENG−/− (D and E), or shENG (F) PASMC cells were plated on dishes coated with fibronectin, laminin, or collagen for 30 min, fixed, and stained with violet crystal. Cell spreading was normalized and quantified from 3 independent experiments ± SEM.
adhesion kinase (FAK) pathway. FAK phosphorylation at Y397 was decreased in CRISPR-induced endoglin knockout PASMC cells during migration (Figure 4B; Figure IV A in the online-only Data Supplement) and spreading (Figure 4C; Figure IVB in the online-only Data Supplement). As loss of endoglin decreased PASMC cells spreading on different ECM components (Figure 3D through 3F), we investigated FAK signaling in these contexts. Consistently, loss of endoglin decreased FAK phosphorylation in the context of fibronectin, laminin, or collagen (Figure 4D; Figure IVC and IVD in the online-only Data Supplement). These effects were specifically because of loss of endoglin, as restoring endoglin expression rescued FAK phosphorylation in CRISPR-induced endoglin knockout PASMC cells (Figure IVE in the online-only Data Supplement). As extracellular signal-regulated kinase (ERK)37 and p3838 are downstream of FAK, we investigated the effect of loss of endoglin on the activation of ERK and p38. ERK and p38 phosphorylation were also decreased in the PASMC cells with CRISPR-induced endoglin knockout (Figure IVF through IVH in the online-only Data Supplement) or shRNA-mediated silencing of endoglin expression (Figure IVI through IVK in the online-only Data Supplement). These data indicate that endoglin promotes FAK pathway signaling in VSMCs.

We then investigated whether regulation of the FAK pathway is the mechanism by which endoglin regulates VSMCs recruitment and spreading. Dominant negative FAK (Y397F; Figure IVL in the online-only Data Supplement) dramatically
decreased control PASMC recruitment by (Figure 4E) and spreading on (Figure 4F) HMEC-1 ECs. However, in the PASMCs with loss of endoglin that already exhibited decreased FAK activation (Figure 4B through 4D; Figure IVA through IVD in the online-only Data Supplement), dominant negative FAK had attenuated effects on VSMCs recruitment and spreading (Figure 4E and 4F). Furthermore, 10 μmol/L of the FAK Y397 phosphorylation inhibitor, Y15, partially inhibited FAK phosphorylation at the Y397 site in sh-nontargeted control PASMC cells to the basal level observed in shENG PASMCs (Figure IV in the online-only Data Supplement) without causing dramatic cell apoptosis. Consistently, Y15 decreased recruitment (Figure 4G) and spreading (Figure 4H) in the sh-nontargeted control PASMC cells to the basal level of shENG PASMCs, while further inhibiting shENG PASMCs recruitment (Figure 4G) and spreading (Figure 4H). The more dramatic effects of Y15 on recruitment in shENG PASMC cells may reflect the total FAK inhibition here (Figure IV in the online-only Data Supplement) and the longer time scale of these studies (hours) relative to the spreading studies (minutes). In addition, consistent with a role for FAK and downstream ERK and p38 mediating the effects of loss of endoglin expression, the ERK inhibitor, U0126, and p38 inhibitor, SB203580, also inhibited PASMC migration (Figure IV in the online-only Data Supplement). These data suggest that endoglin promotes VSMC recruitment and spreading at least partially via the FAK pathway.

Endoglin Promotes Different Integrin Subunits Expression

As the kinase activity of FAK is regulated through Y397 autophosphorylation on integrin α and β subunits clustering and further activation of β integrins, we examined the effect of endoglin expression on integrin subunit expression. The mRNA of most integrin subunits were decreased in PASMC cells on loss of endoglin expression (Figure VA in the online-only Data Supplement). Consistently, the protein levels of some integrin subunits whose mRNA levels were downregulated were also decreased in PASMC cells on loss of endoglin expression, including α5, αv, β1, and β3 (Figure 5A; Figure VB in the online-only Data Supplement). Furthermore, the cell surface integrin β1 and α5 subunits were also decreased in ENG−/− cells (Figure VC and VD in the online-only Data Supplement). However, for integrin α6 and α11, whose mRNA were increased in PASMCs lacking endoglin, the protein level of α11 was slightly increased (Figure VE in the online-only Data Supplement), whereas α6 was decreased (Figure VF in the online-only Data Supplement), suggesting other post-transcriptional regulation.

Our data have demonstrated that loss of endoglin decreased FAK signaling and VSMC spreading in the context of different ECM components. As the integrin β1 subunit forms complexes with different integrin α subunits to serve as receptors for different ECM components, we investigated whether endoglin’s function is through integrins, especially through the integrin β1 subunit. shRNA-directed knockdown of integrin β1 (Figure 5B) decreased FAK phosphorylation (Figure 5C and 5D) and recruitment (Figure 5E) in control PASMC cells. However, in ENG−/− PASMC cells, which have lower β1 integrin levels, loss of β1 integrin had attenuated effects (Figure 5C through 5E). In a reciprocal manner, overexpressing integrin β1 increased phosphorylation of FAK (Figure 5F) and recruitment (Figure 5G) in control PASMCs. However, overexpression of integrin β1 only slightly rescued FAK signaling and recruitment in ENG−/− PASMC cells (Figure 5F and 5G), suggesting that besides β1 integrin, other integrin subunits regulated by endoglin are involved in endoglin regulated VSMC recruitment. In addition, endoglin interacted with endogenous β1 integrin in ENG−/− PASMC cells overexpressing hemagglutinin-endoglin (Figure 5H). This interaction was not dependent on the RGD (arginine-glycine-aspartic acid) domain on human endoglin, as mutation of RGD to TAD (threonine-alanine-aspartic acid) had no effect on the endoglin and β1 integrin interaction (Figure 5H), consistent with the lack of conservation of the RGD domain across species (Figure VG in the online-only Data Supplement). Furthermore, endogenous endoglin interacted with endogenous β1 integrin as determined using proximity ligation assays (Figure 5I and 5J). Loss of endoglin also decreased the interaction between endogenous β1 integrin and FAK (Figure 5K). Collectively, these data support that endoglin promotes VSMC recruitment and spreading at least in part through regulation of the integrin-FAK pathway.

Endoglin Promotes VSMC Recruitment and Blood Vessels Maturation In Vivo

To investigate whether endoglin promotes VSMC recruitment to and spreading on ECs in vivo, we injected sh-nontargeted control or shENG PASMCs intravenously into day 10 chicken embryos and observed their recruitment to chorioallantoic membrane arterioles within 24 hours. Compared with the sh-nontargeted control PASMC, shRNA-mediated silencing of endoglin expression dramatically decreased PASMC recruitment to the blood vessels (Figure 6A and 6B). Furthermore, although the recruited control PASMC cells spread and covered the blood vessels, shRNA-mediated silencing of endoglin expression decreased PASMC spreading on the blood vessels (Figure 6A and 6C, red arrows). These data indicate that endoglin in VSMCs promotes VSMC recruitment and blood vessel maturation in vivo.

Discussion

Collectively, we determined here that endoglin is robustly expressed in VSMCs, which promotes VSMC recruitment and spreading on endothelial tubes during angiogenesis (Figure 6D). As we have determined previously that in ECs, endoglin cross talks with fibronectin/integrin α5β1 to regulate endothelial migration and stabilize the newly formed tubes before VSMC and other pericyte recruitment, these studies provide strong support for endoglin’s roles in the maturation of blood vessels.

Although a few prior studies identified endoglin’s roles in VSMCs, including a role in VSMC adhesion to ECs, and VSMC recruitment, the functions and mechanism of action of endoglin in VSMCs during angiogenesis are still largely unknown. To obtain unbiased insight into how endoglin regulates VSMCs function, we utilized an unbiased bioinformatics
analysis of RNA-SEQ data comparing wild-type and endoglin loss of function VSMCs. In this analysis, cell movement was the function most affected by loss of endoglin expression, suggesting a role in inhibiting migration. This is consistent with the key role of cell migration plays in VSMC recruitment during angiogenesis. In the Kyoto Encyclopedia of Genes and Genomes pathway analysis, there were 12 pathways significantly affected by loss of endoglin (Figure 4A). Some of these pathways have been reported previously to be regulated by endoglin. For example, regulation of the TGF-β signaling was expected as endoglin is a TGF-β superfamily coreceptor, mediating TGF-β1 and BMP-9/10 signaling.7,8 In addition, cytokine signaling was supported by the prior observation that endoglin is involved in BMP9 regulated SDF1/CXCR4 chemokine signaling,41 promoting CXCL12-mediated leukocyte adhesion and transmigration through ECs.42 Furthermore, regulation of cancer pathways is supported by endoglin’s involvement in cancer progression.43,44 Interestingly, ECM–receptor interaction and focal adhesion pathways were the top 2 pathways affected by loss of endoglin. These 2 pathways play a central role in cell migration,45–47 adhesion,48,49 and spreading,50 3 key steps during VSMCs recruitment during angiogenesis that are all regulated by integrin–FAK, suggesting regulation of the integrin–FAK pathway as the mechanism by which

Figure 5. Endoglin promotes integrin expression. A, Nontargeted control (NTC) and ENG−/− pulmonary artery smooth muscle cell (PASMC) were plated in dishes and cultured for the indicated times, and the resulting cell lysates analyzed with the indicated antibodies. B, Stable knockdown of integrin β1 using lentivirus in NTC and ENG−/− PASMC cells, knockdown efficiency determined using Western blot. The results are representative of 3 dependent experiments. C and D, shNTC and shIntegrin β1 PASMC cells were plated on dishes and cultured for 1 h, and the cell lysates were analyzed with the indicated antibodies. Quantitative data are from 3 independent experiments ± SEM (D). P values were obtained by 2-tailed Student t test, and the statistical interaction between endoglin and integrin β1 expression was obtained by 2-way ANOVA analysis. E, shNTC and shIntegrin β1 PASMC cells recruitment by HMEC-1 endothelial cells was normalized and quantified from 3 independent experiments ± SEM. The statistical interaction between endoglin and integrin β1 expression was obtained by 2-way ANOVA analysis. F, NTC and ENG−/− PASMC cells transfected with integrin β1 for 24 h were plated on dishes and cultured for 1 h, and the cell lysates were analyzed with the indicated antibodies. The results are representative of 3 independent experiments. G, NTC and ENG−/− PASMC cells were transfected with integrin β1, and PASMC recruitment by HMEC-1 endothelial cells was normalized and quantified from 3 independent experiments ± SEM. H, Immunoprecipitates were prepared from ENG−/− cells overexpressing hemagglutinin (HA)-tagged wild-type endoglin or endoglin RGD (arginine-glycine-aspartic acid) to TAD (threonine-alanine-aspartic acid) mutant with anti-HA antibody, HA-endoglin, and β1 integrin were detected in immunoprecipitates (IP) and cell lysates by Western blot analysis. I and J, Interaction between endogenous endoglin and β1 integrin was assessed in NTC and ENG−/− PASMC cells by Duolink proximity ligation assay. Nuclei were stained using DAPI (4',6-diamidino-2-phenylindole). P values were obtained by 2-tailed Student t test from 3 independent experiments. K, Interaction between endogenous FAK and β1 integrin was assessed in NTC and ENG−/− PASMC cells by Duolink proximity ligation assay. P values were obtained by 2-tailed Student t test from 3 independent experiments.
endoglin regulates VSMCs recruitment. Indeed, we determined that loss of endoglin inhibits VSMCs migration and spreading. However, loss of endoglin only slightly increased VSMCs adhesion to ECs (Figure 3A and 3B). Consistent with this observation, our unbiased bioinformatics analysis demonstrated that CRISPR-induced endoglin knockout did not significantly ($P>0.05$) affect cell adhesion molecule pathways (Table I and Figure IId in the online-only Data Supplement), with the expression of some adhesion molecules mediating adhesion to ECs actually increasing, including ICAM1 (intercellular adhesion molecule 1), L1CAM (L1 cell adhesion molecule), and PECAM1 (platelet and endothelial cell adhesion molecule 1; Figure IId in the online-only Data Supplement).

In terms of the molecular mechanism by which endoglin regulates VSMCs recruitment, based on our RNA-SEQ data, we determined that the integrin–FAK pathway plays a central role in endoglin-regulated VSMC recruitment, migration, and spreading (Figure 6E). Endoglin has been reported to regulate the FAK pathway by different mechanisms in different cell contexts. In ECs, endoglin inhibits cell migration via regulating the composition of focal adhesions. $^{12}$ We have demonstrated previously that TGF-$eta$ promotes internalization of endoglin/integrin $\alpha_5\beta_1$ complex to enhance FAK signaling. $^{14}$ In Ewing sarcoma and melanoma, endoglin enhances $\beta_3$ integrin expression and promotes FAK pathway to maintain tumor cell plasticity and promotes tumor invasion. $^{51}$ In the context of VSMCs, we have observed here that multiple integrin subunits were transcriptionally silenced by loss of endoglin expression in VSMCs. Among them, $\beta_1$ integrin, which can form complexes with multiple $\alpha$ subunits to serve as receptors for several ECM components, was dramatically decreased. This may explain why endoglin can regulate FAK signaling (Figure 4D; Figure IVC and IVD in the online-only Data Supplement) and VSMC biology (Figure 3D through 3F) in the context of different ECM components. In line with the effects on FAK signaling, signaling to ERK and p38, $^{37,38,52}$

Figure 6. Endoglin promotes blood vessel maturation in vivo. A–C, sh-nontargeted control (NTC) and shENG pulmonary artery smooth muscle cells (PASMC) were injected intravenously into the allantoic vein of day 10 chicken embryos and their recruitment to the arterioles of the chorioallantoic membrane was monitored 24 h later. Percentage of PASMC recruitment (A and B) and spreading (A and C) were quantified from 3 independent experiments ± SEM. D, Schematic of endoglin-regulated vascular smooth muscle cells (VSMC) biology during angiogenesis. E, Schematic of the proposed model by which endoglin regulates VSMC function during angiogenesis.
explain why blood vessels in HHT patients are fragile and how

In addition, we have determined previously that endoglin suppresses migration in ECs. These differences are likely to be because of context-dependent mechanisms by which endoglin regulates biology. For example, endoglin inhibits EC migration via interaction with zyxin to alter the composition of focal adhesions. However, we determined here that in VSMCs, endoglin promotes VSMC migration and spreading via promoting integrin expression and focal adhesion pathway signaling. In addition, we have determined previously that endoglin antagonized ERK signaling to inhibit endothelial migration via β-arrestin-2 and TGF-β pathways, whereas here we determine that endoglin promotes ERK signaling potentially downstream of integrin/FAK in VSMCs. One of the contextual differences could be the presence of different interacting receptors in VSMCs and ECs. For example, in ECs, endoglin is a coreceptor for ALK1 and many functions of endoglin in ECs are mediated through ALK1, including effects on migration and proliferation. However, Endoglin and ALK1 both bind the TGF-β superfamily ligand, BMP-9, a quiescent signaling factor that inhibits cell migration in ECs. However, in VSMCs, BMP-9 (Figure 2H) or an ALK1 inhibitor (Figure 2I) had no significant effects on migration, suggesting that VSMCs do not express or express very low levels of ALK1. The cell context-dependent functions of endoglin in VSMCs relative to ECs is important for blood vessels maturation during angiogenesis. In the later stages of angiogenesis (resolution phase), ECs decrease migration and proliferation to finish tubulogenesis, whereas VSMCs increase migration and spreading to facilitate recruitment by immature blood vessels. These distinct cellular behaviors, especially cell movement, between ECs and VSMCs cooperate to mature the newly formed blood vessels. The distinct roles of endoglin in endothelial and VSMC biology defined here may provide a novel mechanism for coordinating these functions.

Mutations in endoglin and ALK1 result in hereditary hemorrhagic telangiectasia (HHT). The important role of endoglin in VSMC recruitment and spreading described here may explain why blood vessels in HHT patients are fragile and how recurrent bleeding occurs (Figure 6D). However, endoglin regulates VSMC recruitment in a TGF-β and ALK1-independent manner (Figure 2H and 2I). Furthermore, endoglin and ALK1 heterozygous mice have a distinct pulmonary and hepatic angiogenic profiles and response to anti-VEGF treatment. Thus, besides functioning as a coreceptor for ALK1, endoglin may regulate angiogenesis and HHT at least partially in an ALK1-independent manner. Indeed, ALK1 is also involved in VSMC recruitment, as the ALK1 inhibitor, ALK-FC, increases vessel pericyte coverage, suggesting that ALK1 inhibits VSMC recruitment. The distinct roles and mechanism of endoglin and ALK1 in HHT could be used as the basis for developing therapies for different molecular causes of HHT. For example, the current studies suggest that targeting FAK may be a rationale approach for type I HHT patients, who have endoglin mutations. The roles and mechanism by which ALK1 regulates VSMC recruitment remain to be explored.

Collectively, these studies provide novel insights into how endoglin regulates angiogenesis in the context of VSMCs, and how its disruption contributes to the pathophysiology of endoglin-associated vascular diseases, including hereditary hemorrhagic telangiectasia and cancer-associated angiogenesis.

Acknowledgments
We are grateful to Dr Elisabetta Dejana for providing mouse embryonic endothelial cells, Tyson Foods Inc., for providing the fertilized eggs to the Zijlstra Laboratory, and to Dr Michael Gatza for initial bioinformatic analysis of the RNA-SEQ data.

Sources and Funding
This work was supported in part by Komen for the Cure Grants CCR15333124 (Dr Tian), HHT Young Scholar Award (Dr Tian), and NIH/NCl (National Cancer Institute/National Institutes of Health) grants CA135006 (Dr Blobe), CA143081 (Dr Zijlstra).

Disclosures
None.

References
1. Conway EM, Colleen D, Carmelit P. Molecular mechanisms of blood vessel growth. Cardiovasc Res. 2001;49:507–521.
2. Cheifetz S, Bellon T, Calcès C, Vera S, Bernabeu C, Massagué J, Letarte M. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem. 1992;267:19027–19030.
3. Scharpfenecker M, van Dinther M, Liu Z, van Bezooijen RL, Zhao Q, Pukac L, Löwik CW, ten Dijke P. BMP-9 and BMP10 as functional activators of the orphan activin receptor type II system in human endothelial cells. J Biol Chem. 1999;274:584–594.
4. Barbara NP, Wrana JL, Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem. 1999;274:584–594.
5. Letamendia A, Lastres P, Botella LM, Raab U, Langa C, Velasco B, Artisano L, Bernabeu C. Role of endoglin in cellular responses to transforming growth factor-beta. A comparative study with betaglycan. J Biol Chem. 1998;273:33011–33019.
6. Guerrero-Esteo M, Sanchez-Elsner T, Letamendia A, Bernabeu C. Extraglomerular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II. J Biol Chem. 2002;277:29197–29209. doi: 10.1074/jbc.M111991200.
7. David L, Mallet C, Mazereu B, Feige JJ, Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood. 2007;109:1953–1961. doi: 10.1182/blood-2006-07-034124.
26. Choi EJ, Chen W, Jun K, Arthur HM, Young WL, Su H. Novel brain
24. Lepore JJ, Cheng L, Min Lu M, Mericko PA, Morrisey EE, Parmacek MS.
23. Braverman IM, Keh A, Jacobson BS. Ultrastructure and three-dimensional
17. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA,
15. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG,
14. Tian H, Mythreye K, Golzio C, Katsanis N, Blobe GC. Endoglin mediates
12. Conley BA, Koleva R, Smith JD, Kacer D, Zhang D, Bernabéu C, Vary
10. Pece-Barbara N, Vera S, Kathirkamathamby K, Liebner S, Di Guglielmo
8. Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G,

2009;238:2479–2493. doi: 10.1002/dvdy.22066.

Endoglin plays distinct roles in vascular smooth muscle cell recruitment
function of the cytosolic domain. J Biol Chem. 2004;279:27440–27449.

Endoglin controls cell migration and composition of focal adhesions:

1125

Tian et al

Endoglin Promotes Vascular Maturation

26. Mancini ML, Verdi JM, Conley BA, Nicola T, Spicer DB, Oxburgh LH,

25. Langa C, Fabra A, Letarte M, Bernabéu C. Endoglin modulates cell-

21. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG,

20. Smith JD, Kacer D, Zhang D, Bernabéu C, Vary CP. Endoglin controls cell migration and composition of focal adhesions:

19. Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G,

18. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA,

16. McDonald J, Bayrak-Toydemir P, Pyrierz RE. Hereditary hemorrhagic telangiectasia: an overview of diagnosis, management, and pathogenesis. Genet Med. 2011;13:457–46. doi: 10.1038/gim.2010.131.

15. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG,

14. Tian H, Mythreye K, Golzio C, Katsanis N, Blobe GC. Endoglin mediates fibronectin/α5β1 and TGF-β pathway crosstalk in endothelial cells. J Biol Chem. 2012;287:3885–3900. doi: 10.1074/jbc.M112.348562.

13. Sanz-Rodriguez F, Guererro-Esteo M, Botella LM, Banville D, Vary CP, Bernabéu C. Endoglin regulates cytoketical organization through binding to ZRP-1, a member of the Lim family of proteins. J Biol Chem. 2004;279:32858–32868. doi: 10.1074/jbc.M40483200.

12. Conley BA, Koleva R, Smith JD, Kacer D, Zhang D, Bernabéu C, Vary CP. Endoglin controls cell migration and composition of focal adhesions:

11. Lee NY, Blobe GC. The interaction of endoglin with beta-arrestin2 regulates transforming growth factor-beta-mediated ERK activation and migration in endothelial cells. J Biol Chem. 2007;282:21507–21517. doi: 10.1074/jbc.M701176200.

10. Pece-Barbara N, Vera S, Kathirkamathamby K, Liebner S, Di Guglielmo

9. Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G,

8. Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G,

7. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA,

6. McDonald J, Bayrak-Toydemir P, Pyrierz RE. Hereditary hemorrhagic telangiectasia: an overview of diagnosis, management, and pathogenesis. Genet Med. 2011;13:457–46. doi: 10.1038/gim.2010.131.

5. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG,

4. Tian H, Mythreye K, Golzio C, Katsanis N, Blobe GC. Endoglin mediates fibronectin/α5β1 and TGF-β pathway crosstalk in endothelial cells. J Biol Chem. 2012;287:3885–3900. doi: 10.1074/jbc.M112.348562.

3. Torsney E, Charlton R, Parnams D, Collis M, Arthur HM. Inducible expres-
sion of human endoglin during inflammation and wound healing in vivo. Inflamm Res. 2002;51:464–470.

2. Mazimbrada J, Rittà M, Mondini M, De Andrea M, Azzimontib M, Borgogna

1.106.131.210.119.

8. Lebrin F, Goumans MJ, Ionter L, Carvalho RL, Valdimarsdottir G,

7. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA,

6. McDonald J, Bayrak-Toydemir P, Pyrierz RE. Hereditary hemorrhagic telangiectasia: an overview of diagnosis, management, and pathogenesis. Genet Med. 2011;13:457–46. doi: 10.1038/gim.2010.131.

5. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG,

4. Tian H, Mythreye K, Golzio C, Katsanis N, Blobe GC. Endoglin mediates fibronectin/α5β1 and TGF-β pathway crosstalk in endothelial cells. J Biol Chem. 2012;287:3885–3900. doi: 10.1074/jbc.M112.348562.

3. Torsney E, Charlton R, Parmanms D, Collis M, Arthur HM. Inducible expres-
sion of human endoglin during inflammation and wound healing in vivo. Inflamm Res. 2002;51:464–470.

2. Mazimbrada J, Rittà M, Mondini M, De Andrea M, Azzimontib M, Borgogna

1. Braverman IM, Keh A, Jacobson BS. Ultrastructure and three-dimensional

organization of the telangiectasias of hereditary hemorrhagic telangiectasia. J Invest Dermatol. 1990;95:422–427.

Leontjeva LS, Leong LM, Meric-DA, Morrisey EE, Parvenue M. High-efficiency somatic maturation in smooth muscle cells and cardiac myocytes in SM2alpha-Cre transgenic mice. Genesis. 2005;41:179–184. doi: 10.1002/gene.201112.

Milton I, Ouyang D, Allen CJ, Yasakag NE, Gossage JR, Alleyne CH Jr, Seki T. Age-dependent lethality in novel transgenic mouse models of central nervous system arteriovenous malformations. Stroke. 2012;43:1432–1435. doi: 10.1161/STROKEAHA.111.670724.

Choi EI, Chen W, Jun K, Arthur HM, Young WL, Su H. Novel brain arteriovenous malformation mouse models for type 1 hereditary hemorrhagic telangiectasia. PLoS One. 2014;9:e88511. doi: 10.1371/journal.pone.0088511.

Mancini ML, Terzic A, Conley BA, Oxburgh LH, Nicola T, Vary CP. Endoglin plays distinct roles in vascular smooth muscle cell recruitment and regulation of arteriovenous identity during angiogenesis. Dev Dyn. 2009;238:2479–2493. doi: 10.1002/tdy.20266.

28. Mancini ML, Verdi JM, Conley BA, Nicola T, Spicer DB, Oxburgh LH,

27. Tian et al

Endoglin Promotes Vascular Maturation

1125

Endoglin Promotes Vascular Maturation
49. Xie B, Zhao J, Kitagawa M, Durbin J, Madri JA, Guan JL, Fu XY. Focal adhesion kinase activates Stat1 in integrin-mediated cell migration and adhesion. *J Biol Chem*. 2001;276:19512–19523. doi: 10.1074/jbc.M009063200.

50. Disatnik MH, Rando TA. Integrin-mediated muscle cell spreading. The role of protein kinase c in outside-in and inside-out signaling and evidence of integrin cross-talk. *J Biol Chem*. 1999;274:32486–32492.

51. Pardali E, van der Schaft DW, Wiercinska E, Gorter A, Hogendoorn PC, Griffioen AW, ten Dijke P. Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma. *Oncogene*. 2011;30:334–345. doi: 10.1038/onc.2010.418.

52. Teranishi S, Kimura K, Nishida T. Role of formation of an ERK-FAK-paxillin complex in migration of human corneal epithelial cells during wound closure *in vitro*. *Invest Ophthalmol Vis Sci*. 2009;50:5646–5652. doi: 10.1167/iovs.08-2534.

53. David L, Mallet C, Keramidas M, Lamandé N, Gasc JM, Dupuis-Girod S, Plauchu H, Feige JJ, Bailly S. Bone morphogenetic protein-9 is a circulating vascular quiescence factor. *Circ Res*. 2008;102:914–922. doi: 10.1161/CIRCRESAHA.107.165530.

54. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, Li L, Miyazono K, ten Dijke P, Kim S, Li E. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. *Proc Natl Acad Sci USA*. 2000;97:2626–2631.

55. Bourdeau A, Dumont DJ, Letarte M. A murine model of hereditary hemorrhagic telangiectasia. *J Clin Invest*. 1999;104:1343–1351. doi: 10.1172/JCI8088.

56. Urness LD, Sorensen LK, Li DY. Arteriovenous malformations in mice lacking activin receptor-like kinase-1. *Nat Genet*. 2000;26:328–331. doi: 10.1038/1634.

57. Johnson DW, Berg JN, Baldwin MA, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. *Nat Genet*. 1996;13:189–195. doi: 10.1038/ng0696-189.

58. Ardelean DS, Jerkic M, Yin M, Peter M, Nguan B, Kerbel RS, Foster FS, Letarte M. Endoglin and activin receptor-like kinase 1 heterozygous mice have a distinct pulmonary and hepatic angiogenic profile and response to anti-VEGF treatment. *Angiogenesis*. 2014;17:129–146. doi: 10.1007/s10456-013-9383-4.

59. Hawinkels LJ, de Vinuesa AG, Pauwwe M, Kruithof-de Julio M, Wiercinska E, Pardali E, Mezzanotte L, Keereweer S, Braumuller TM, Heijkants RC, Jonkers J, Löwik CW, Goumans MJ, ten Hagen TL, ten Dijke P. Activin receptor-like kinase 1 ligand trap reduces microvascular density and improves chemotherapy efficiency to various solid tumors. *Clin Cancer Res*. 2016;22:96–106. doi: 10.1158/1078-0432.CCR-15-0743.

---

**Highlights**

- Endoglin is not expressed only in endothelial cells, but also in VSMCs.
- Endoglin promotes VSMCs recruitment during angiogenesis in a cell autonomous manner.
- Endoglin promotes VSMCs recruitment via promoting VSMCs migration and spreading.
- Endoglin promotes integrin/FAK signaling.